Applied Therapeutics Inc
NASDAQ:APLT
Applied Therapeutics Inc
Free Cash Flow
Applied Therapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Applied Therapeutics Inc
NASDAQ:APLT
|
Free Cash Flow
-$94m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$12B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.6B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Applied Therapeutics Inc
Glance View
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
See Also
What is Applied Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-94m
USD
Based on the financial report for Mar 31, 2025, Applied Therapeutics Inc's Free Cash Flow amounts to -94m USD.
What is Applied Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-14%
Over the last year, the Free Cash Flow growth was -40%.
You don't have any saved screeners yet